HighTower Advisors’s Novo Nordisk NVO Stock Holding History

HighTower Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$418	–	3872
2025 Q3	$418	Buy	+100	New	+$5.85K	﹤0.01%	3781
2024 Q1	–	Sell	-1,100	Closed	-$37K	–	3893
2023 Q4	$37K	Buy	1,100 +340	+45%	+$33.6K	﹤0.01%	3346
2023 Q3	$128K	Buy	760 +750	+7,500%	+$66.1K	﹤0.01%	3039
2023 Q2	$15.7K	Buy	+10	New	+$817	﹤0.01%	3268
2022 Q1	–	Sell	-26	Closed	-$4K	–	3596
2021 Q4	$4K	Buy	+26	New	+$1.41K	﹤0.01%	3208

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

HighTower Advisors's NVO Position: Q1 2026 in Review

HighTower Advisors increased its Novo Nordisk (NVO) stake by 28% in Q1 2026, buying an estimated $2.46M and bringing the position to 235,066 shares worth $8.64M. The position accounts for 0.01% of the portfolio, ranked #949.

HighTower Advisors first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $72.9M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

HighTower Advisors held 235,066 shares of Novo Nordisk worth $8.64M as of Q1 2026.
HighTower Advisors bought 51,865 Novo Nordisk shares in Q1 2026, an estimated $2.46M.
Novo Nordisk made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #949 holding.
HighTower Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
HighTower Advisors's Novo Nordisk position peaked at $72.9M in Q2 2024.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.